
Aro Biotherapeutics Appoints Glenn Crater, MD, as Chief Medical Officer
Press Release – January 07, 2025 – PHILADELPHIA – Aro Biotherapeutics, a clinical-stage biotechnology company working to develop potent, tissue-targeted medicines, today announced the appointment of Glenn D. Crater, MD, as chief medical officer (CMO). Dr. Crater will lead the development of Aro’s pipeline of Centyrin-based, tissue-targeted medications, including the company’s lead product candidate ABX1100, a novel potential treatment for Pompe disease. “In addition, I … Continue reading Aro Biotherapeutics Appoints Glenn Crater, MD, as Chief Medical Officer